- Home
- PLX vs CTNM Comparison
PLX vs CTNM Comparison
Compare PLX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CTNM
- Stock Information
- Founded
- PLX 1993
- CTNM 2009
- Country
- PLX United States
- CTNM United States
- Employees
- PLX N/A
- CTNM N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CTNM
- Sector
- PLX Health Care
- CTNM
- Exchange
- PLX Nasdaq
- CTNM Nasdaq
- Market Cap
- PLX 122.6M
- CTNM 122.9M
- IPO Year
- PLX 1998
- CTNM 2024
- Fundamental
- Price
- PLX $1.54
- CTNM $3.88
- Analyst Decision
- PLX Strong Buy
- CTNM Strong Buy
- Analyst Count
- PLX 1
- CTNM 4
- Target Price
- PLX $15.00
- CTNM $22.50
- AVG Volume (30 Days)
- PLX 1.2M
- CTNM 213.2K
- Earning Date
- PLX 08-13-2025
- CTNM 08-12-2025
- Dividend Yield
- PLX N/A
- CTNM N/A
- EPS Growth
- PLX N/A
- CTNM N/A
- EPS
- PLX 0.05
- CTNM N/A
- Revenue
- PLX $59,764,000.00
- CTNM N/A
- Revenue This Year
- PLX $65.02
- CTNM N/A
- Revenue Next Year
- PLX $57.34
- CTNM N/A
- P/E Ratio
- PLX $31.98
- CTNM N/A
- Revenue Growth
- PLX 0.18
- CTNM N/A
- 52 Week Low
- PLX $0.82
- CTNM $3.35
- 52 Week High
- PLX $3.10
- CTNM $21.92
- Technical
- Relative Strength Index (RSI)
- PLX 47.41
- CTNM N/A
- Support Level
- PLX $1.32
- CTNM N/A
- Resistance Level
- PLX $1.67
- CTNM N/A
- Average True Range (ATR)
- PLX 0.11
- CTNM 0.00
- MACD
- PLX 0.04
- CTNM 0.00
- Stochastic Oscillator
- PLX 62.86
- CTNM 0.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.